Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: If each potential infringer has been given a ballpark figure for a license,

Maybe the license prices have NOT gone up as we hoped, so it's still ok for many companies to wait for the USPTO decision?



I would expect the prices to be those given initially to enable a negotiated settlement.

The problem I have is how can any FD, with falling profits, justify a delay in licensing in the knowledge that the fee will increase substantially in the event of revalidation.

I can see the logic for licensing now because the patents are still valid, but to delay in the hope of invalidation, given the available information, would appear to be a gamble in breach of the fiduciary duty to shareholders of the respective companies put on notice.

It is humbly suggested that it would be far easier to defend the purchase of a license pre USPTO decision than it would if purchaesd after USPTO validation.





Be well





Share
New Message
Please login to post a reply